220 Stocks to Sell Today
Free Report for Zacks.com
Visitors Only

Overall, Zacks Rank #5 Strong Sells perform 6X worse than the market. Are any of these portfolio killers lurking among the stocks you're holding or considering? Find out today for free.


No cost, no obligation to buy anything ever.
Privacy Policy
Close This Panel X

Are you a new Zacks Member or a visitor to Zacks.com?

Recent Quotes

No Recent Quote currently available

My Portfolio

My Portfolio Tracker

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Stocks on the Move 06/19/2013

Company Name Symbol %Change
SONIC FOUNDR SOFO
4.40%
SUPPORTCOM I SPRT
3.75%
UNISYS CORP UIS
3.31%
SHORETEL INC SHOR
3.22%
GREEN MOUNTA GMCR
3.13%

Earnings Preview: Baxter

by Zacks Equity Research

January 22, 2013 | Comments : 0 Recommended this article: (0)

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

Baxter International (BAX - Analyst Report) is set to report its fourth-quarter 2012 results before the opening bell on Thursday, Jan 24. Let’s see how things are shaping up prior to the announcement.

In the last quarter, the company did not post any earnings surprise reflecting indifferent performance by the company.

Factors to Consider this Past Quarter

The news regarding Baxter still remains somewhat mixed. On the positive side, Baxter’s focus on life-sustaining products which are not commoditized, partly insulate it from an economic downturn. The company is able to generate recurring revenues, and consistent cash flow, due to its focus on chronic diseases. Among other positive factors, Baxter retains a strong product pipeline with several products in late-stage clinical development.

On the flip side, despite resilience in certain sub-segments, we are concerned about relative stagnation in sales, a slightly somber outlook for hospital spending and tightening of reimbursement.

Improved execution has lifted sentiment somewhat toward Baxter. It is a good bet for value investors willing to wait as fundamentals improve further.

Earnings Whispers?

Our proven model does not conclusively show that Baxter is likely to beat earnings estimates this quarter. That is because a stock needs to have both a positive Earnings ESP (Expected Surprise Prediction) (Read: Zacks Earnings ESP: A Better Method) and a Zacks Rank of #1, 2 or 3 for this to happen. This is not the case here as you will see below.

Zacks Earnings ESP: The Most Accurate estimate stands at $1.25, while the Zacks Consensus Estimate is pegged at $1.26. This comes to a difference of -0.79%.

Zacks Rank #3 (Hold).Baxter’s Zacks Rank #3 (Hold) lowers the predictive power of ESP. The Zacks Rank #3 together with negative ESP earnings makes surprise prediction difficult.

Other Stocks to Consider

Here are some other companies you may want to consider as our model shows they have the right ingredients to post an earnings beat this quarter:

NuVasive Inc.(NUVA - Snapshot Report), Earnings ESP of 72.73% and Zacks Rank #1 (Strong Buy)

Hill-Rom Holdings, Inc.(HRC - Snapshot Report), Earnings ESP of 2.27% and Zacks Rank #2 (Buy)

Becton, Dickinson and Company (BDX - Analyst Report), Earnings ESP of 3.25% and Zacks Rank #2 (Buy).

Email Print Share Rate Pos Rate Neg

Read/Post Comments (0) | Recommended this article (0)

Please login to Zacks.com or register to post a comment.

Zacks Research is Reported On:

Zacks Investment Research

is an A+ Rated BBB

Accredited Business.